Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December ...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F ») Daix (France), New York City (New York, États-Unis), le 15 avril 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d'autres maladies avec un besoin médical non satisfait, annonce aujourd’hui avoir déposé son Document d’Enreg...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 15, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total am...
Reporting on acquisition of treasury shares Regulated information Aalst, Belgium, April 11, 2025 – In accordance with article 8:4 of the Royal Decree of April 2, 2019 executing the Belgian Code of Companies and Associations, Ontex hereby discloses information in relation to its program to buy back treasury shares, which was announced on November 25, 2024. During the work week ending on April 11, 2025, Ontex repurchased 118,758 shares on the regulated market of Euronext Brussels, as set out in the table below. Date# sharesAverageprice (in €)Minimumprice (in €)Maximumprice (in €)Total value...
Rapportering betreffende inkoop van eigen aandelen Gereglementeerde informatie Aalst, België, 11 april 2025 – In overeenstemming met artikel 8:4 van het Koninklijk Besluit tot uitvoering van het Wetboek van Vennootschappen en Verenigingen, maakt Ontex informatie bekend in verband met zijn programma om eigen aandelen in de kopen, dat was aangekondigd op 25 november 2024. In de loop van de werkweek eindigend op 11 april 2025, werden 118.758 eigen aandelen ingekocht op de gereguleerde markt van Euronext Brussel, volgens het hieronder beschreven schema. Datum# aandelenGemiddel...
Ontex announces details for its Q1 2025 results publication Aalst, Belgium, April 11, 2025 – Ontex Group NV, a leading international developer and producer of personal care products, will share its results for the first quarter of 2025 at 07:00 CEST / 06:00 BST on Wednesday, April 30, 2025. Management will host a webcast for investors and analysts on the same day at 12:00 CEST / 11:00 BST. Click on the following link to attend the presentation from your laptop, tablet or mobile device: . A replay of the webcast will be available at the same link shortly after the conclusion of the live pre...
Ontex kondigt details aan voor de resultatenpublicatie van het 1ste kwartaal van 2025 Aalst, België, 11 april 2025 – Ontex Group NV, een toonaangevende internationale ontwikkelaar en producent van persoonlijke verzorgingsproducten, zal zijn resultaten van het eerste kwartaal van 2025 delen om 07:00 uur CEST op woensdag 30 april 2025. Het directiecomité zal op dezelfde dag een Engelstalige webcast voor investeerders en analisten opzetten om 12:00 uur CEST. Klik op volgende link om de presentatie bij te wonen vanop uw laptop, tablet of mobiel apparaat: . Een herhaling van de webcast zal kort...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.